100 related articles for article (PubMed ID: 20514797)
1. Treatment of basal cell carcinoma of the nasal pyramid with intralesional interferon alfa-2b.
Fernández-Vozmediano JM; Armario-Hita JC
J Drugs Dermatol; 2010 Apr; 9(4):381-4. PubMed ID: 20514797
[TBL] [Abstract][Full Text] [Related]
2. Use of recombinant interferon alfa-2b in the treatment of basal cell carcinoma.
Chimenti S; Peris K; Di Cristofaro S; Fargnoli MC; Torlone G
Dermatology; 1995; 190(3):214-7. PubMed ID: 7599384
[TBL] [Abstract][Full Text] [Related]
3. The effect of an intralesional sustained-release formulation of interferon alfa-2b on basal cell carcinomas.
Edwards L; Tucker SB; Perednia D; Smiles KA; Taylor EL; Tanner DJ; Peets E
Arch Dermatol; 1990 Aug; 126(8):1029-32. PubMed ID: 2383027
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the effects of intralesional interferon alfa-2a, 2b and the combination of 2a and 2b in the treatment of basal cell carcinoma.
Alpsoy E; Yilmaz E; Başaran E; Yazar S
J Dermatol; 1996 Jun; 23(6):394-6. PubMed ID: 8708151
[TBL] [Abstract][Full Text] [Related]
5. Treatment of cutaneous squamous cell carcinomas by intralesional interferon alfa-2b therapy.
Edwards L; Berman B; Rapini RP; Whiting DA; Tyring S; Greenway HT; Eyre SP; Tanner DJ; Taylor EL; Peets E
Arch Dermatol; 1992 Nov; 128(11):1486-9. PubMed ID: 1444502
[TBL] [Abstract][Full Text] [Related]
6. Intralesional alfa-2a interferon therapy for basal cell carcinoma.
Doğan B; Harmanyeri Y; Baloğlu H; Oztek I
Cancer Lett; 1995 May; 91(2):215-9. PubMed ID: 7767912
[TBL] [Abstract][Full Text] [Related]
7. Intralesional interferon therapy for basal cell carcinoma.
Cornell RC; Greenway HT; Tucker SB; Edwards L; Ashworth S; Vance JC; Tanner DJ; Taylor EL; Smiles KA; Peets EA
J Am Acad Dermatol; 1990 Oct; 23(4 Pt 1):694-700. PubMed ID: 2229497
[TBL] [Abstract][Full Text] [Related]
8. Treatment of aggressive basal cell carcinoma with intralesional interferon: evaluation of efficacy by Mohs surgery.
Stenquist B; Wennberg AM; Gisslén H; Larkö O
J Am Acad Dermatol; 1992 Jul; 27(1):65-9. PubMed ID: 1619079
[TBL] [Abstract][Full Text] [Related]
9. Intralesional interferon alfa-2b in the treatment of basal cell carcinoma. Immunohistochemical study on cellular immune reaction leading to tumor regression.
Buechner SA
J Am Acad Dermatol; 1991 May; 24(5 Pt 1):731-4. PubMed ID: 1869644
[TBL] [Abstract][Full Text] [Related]
10. Treatment of basal cell carcinoma with intralesional interferon alfa-2b: an open-label clinical trial.
Maleki M; Layegh P; Kiafar B; Teimoorian M; Darchini-Maragheh E; Razmara M
Expert Rev Anticancer Ther; 2023 Jul; 23(7):753-760. PubMed ID: 37256542
[TBL] [Abstract][Full Text] [Related]
11. Intralesional interferon alfa-2b treatment of keratoacanthomas.
Oh CK; Son HS; Lee JB; Jang HS; Kwon KS
J Am Acad Dermatol; 2004 Nov; 51(5 Suppl):S177-80. PubMed ID: 15577764
[TBL] [Abstract][Full Text] [Related]
12. Treatment of infiltrating basal cell carcinoma with the combination of intralesional IFNalpha-2b and topical imiquimod 5% cream.
Turan A; Saricaoglu H; Baskan EB; Toker SC; Tunali S
Int J Dermatol; 2009 Feb; 48(2):214-5. PubMed ID: 19200213
[No Abstract] [Full Text] [Related]
13. Long-term follow-up of patients with high-risk facial basal cell carcinoma treated with interferon.
Sánchez V; Carpio E; Fardales VE; Martínez B; Arias AI; Brito E; Bermudez N; Rodríguez Y
An Bras Dermatol; 2024; 99(3):391-397. PubMed ID: 38383261
[TBL] [Abstract][Full Text] [Related]
14. Perilesional and topical interferon alfa-2b for conjunctival and corneal neoplasia.
Vann RR; Karp CL
Ophthalmology; 1999 Jan; 106(1):91-7. PubMed ID: 9917787
[TBL] [Abstract][Full Text] [Related]
15. Intralesional interferon alfa-2b for the treatment of genital warts.
Welander CE; Homesley HD; Smiles KA; Peets EA
Am J Obstet Gynecol; 1990 Feb; 162(2):348-54. PubMed ID: 2155531
[TBL] [Abstract][Full Text] [Related]
16. Intralesional interferon alpha-2b in the treatment of basal cell carcinoma and squamous cell carcinoma: revisited.
Kim KH; Yavel RM; Gross VL; Brody N
Dermatol Surg; 2004 Jan; 30(1):116-20. PubMed ID: 14692941
[TBL] [Abstract][Full Text] [Related]
17. Intralesional recombinant interferon beta-1a in the treatment of basal cell carcinoma: results of an open-label multicentre study.
Kowalzick L; Rogozinski T; Wimheuer R; Pilz J; Manske U; Scholz A; Fierlbeck G; Mohr P; Ochsendorf F; Wagner G; Gaus W; Brzoska J; Jablonska S
Eur J Dermatol; 2002; 12(6):558-61. PubMed ID: 12459527
[TBL] [Abstract][Full Text] [Related]
18. Intralesional recombinant alpha 2B interferon in the treatment of human papillomavirus-associated cervical intraepithelial neoplasia.
Stellato G
Sex Transm Dis; 1992; 19(3):124-6. PubMed ID: 1326126
[TBL] [Abstract][Full Text] [Related]
19. Consideration of the cost of interferon alfa-2b in the treatment of basal cell carcinoma.
Shiell A
Australas J Dermatol; 1994; 35(2):71-5. PubMed ID: 7702490
[TBL] [Abstract][Full Text] [Related]
20. Immunohistological evaluation of basal cell carcinoma immunoinfiltrate during intralesional treatment with alpha 2-interferon.
Mozzanica N; Cattaneo A; Boneschi V; Brambilla L; Melotti E; Finzi AF
Arch Dermatol Res; 1990; 282(5):311-7. PubMed ID: 2221983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
